Table 1 Patients’ demographics and clinico-pathological characteristics
Items | Value |
|---|---|
Age (M ± SD, yrs) | 57.9 ± 12.9 |
Gender | |
Male (%) | 132 (71.7) |
Female (%) | 52 (28.3) |
Tumor location | |
Distal stomach (%) | 98 (53.3) |
Non-distal stomach (%) | 86 (46.7) |
Pathological types | |
Adenocarcinoma | |
Histological grade 1/2 | 55 (29.9) |
Well/Moderately differentiated adenocarcinoma (%) | 55 (29.9) |
Histological grade 3/4 | 124 (67.4) |
Low/Undifferentiated adenocarcinoma (%) | 102 (55.4) |
Mucinous adenocarcinoma/signet-ring cell carcinoma | 22 (12.0) |
Others a (%) | 5 (2.7) |
Serosa invasion | |
No (T0, T1, T2) (%) | 27 (14.7) |
Yes (T3, T4) (%) | 157 (85.3) |
Lymph node metastasis | |
No (N0) (%) | 53 (28.8) |
Yes (N1, N2, N3) (%) | 131 (71.2) |
LNR, Median (Range) | 0.33 (0-1) |
Distant Metastasis | |
M0 (%) | 177 (96.2) |
M1 (%) | 7 (3.8) |
TNM stages | |
Early (Stages I, II) (%) | 58 (31.5) |
Advanced (Stages III, IV) (%) | 126 (68.5) |
Surgery | |
Subtotal resection (%) | 159 (86.4) |
Non-Subtotal resection (%) | 25 (13.6) |
Chemotherapy | |
No (%) | 35 (19.0) |
Yes (%) | 149 (81.0) |
Recurrence | |
No (%) | 124 (67.4) |
Yes (%) | 60 (32.6) |
Recurrence location b | |
Local-regional | 37 (61.7) |
Distant | 23 (38.3) |
Clinical status at the end of the follow up | |
Live and without recurrence | 72 (39.1) |
Dead or alive with recurrence | 112 (60.9) |
MT1-MMP expression | |
Negative | 46 (33.3) |
Positive | 138 (66.7) |
CD11b + immunocytes (cells/mm2) | |
Median (range) | 257 (4-2101) |